

## WORKING GROUP MEETING MINUTES: Cost Effectiveness

### Working Group

19<sup>th</sup> March 2021

Meeting details			
Meeting location	MS Teams online		
Meeting date	Friday 19th March 2021		
Meeting time	16.30-17.30 CET		
Chair(s)	Job Van Boven		
Attendees	<table border="0"> <tr> <td>Job Van Boven Brett McQueen Mohsen Sadatsafavi Julia Slejko</td> <td>Jonathan Schelfhout John Haughney Graham Lough</td> </tr> </table>	Job Van Boven Brett McQueen Mohsen Sadatsafavi Julia Slejko	Jonathan Schelfhout John Haughney Graham Lough
Job Van Boven Brett McQueen Mohsen Sadatsafavi Julia Slejko	Jonathan Schelfhout John Haughney Graham Lough		
Objectives			
1	Update from previous meeting		
2	New project possibilities		

Items	
Update from previous meeting	<ol style="list-style-type: none"> <li><b>1. <u>GSK Nucala (mepolizumab) project.</u></b> <ul style="list-style-type: none"> <li>• REG were approached by Armando Partida from GSK about reproducing Campbell, McQueen &amp; Briggs (2014) Case study of Omalizumab Efficacy &amp; Effectiveness.</li> <li>• There has been no further contact with GSK</li> </ul> </li> <li><b>2. <u>REG ICS stepdown project.</u></b> <ul style="list-style-type: none"> <li>• Project developed by Sarah Lucas in the REG Child Health working group.</li> <li>• Decided in previous meeting unlikely to implement CE analysis.</li> </ul> </li> <li><b>3. <u>REG/Novartis Breezhaler project.</u></b> <ul style="list-style-type: none"> <li>• Project developed project by Graham in REG Technologies working group.</li> <li>• In discussion with Novartis.</li> <li>• May be hard to get necessary data.</li> </ul> </li> <li><b>4. <u>Chronic cough project.</u></b></li> </ol>



	<ul style="list-style-type: none"> <li>Chronic cough economic model development by Jonathan Schelfhout. Discussed below.</li> </ul>
<p><b>New project possibilities</b></p>	<p><b><u>Chronic cough project</u></b></p> <ul style="list-style-type: none"> <li>Brett guided through his chronic cough poster at REG Summit estimating economic value of chronic cough therapies.</li> <li>Jonathan updated the group on the work he has been doing with Merck in a health economics model for chronic cough, listing the approach and difficulties faced.</li> <li>The model has been developed to be modified and applicable globally and to different regions / countries.</li> </ul> <p><b><u>Do clinical guidelines consider / incorporate cost effectiveness in their treatment recommendations?</u></b></p> <ul style="list-style-type: none"> <li>Job suggested a potential low-cost REG project of a scoping review highlighting gaps in clinical guidelines where cost of treatment is not considered.</li> <li>A lot of relevance for primary care, who prescribe based on guidelines.</li> <li>Can address low-value care.</li> <li>The project will focus on global perspective.</li> <li>It was agreed upon that this project would focus on COPD guidelines but could then be applied to asthma at a later date.</li> <li>Possible methodology could include longitudinal associated date of guideline release and date of drug recommended.</li> <li>Julia has access to national claims and Medicare data.</li> <li>Could take table and cross over using national claims data.</li> <li>It was agreed that it is better to keep the project unfunded for cheaper access to relevant commercial claims data and avoidance of conflicts of interest.</li> <li>Ideal would be global study, but low- / middle-income countries may not have guidelines available electronically.</li> <li>Methodology needs to be confirmed.</li> <li>Job shared his recently published paper on COPD guidelines</li> </ul>
<p><b>Action Points</b></p>	<ul style="list-style-type: none"> <li>Mohsen will invite Dr Wenjia Chen from the University of Singapore to the group.</li> <li>Graham to send Doodle poll to members to arrange a date / day for monthly WG meeting.</li> <li>Graham will create a new research proposal for the CE in creation of treatment recommendation guidelines.</li> </ul>